Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Expenses (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Operating Expenses for 11 consecutive years, with $79.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 206.43% to $79.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $146.2 million, a 76.55% increase, with the full-year FY2025 number at $146.2 million, up 76.55% from a year prior.
  • Operating Expenses was $79.6 million for Q4 2025 at Cartesian Therapeutics, up from $21.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $79.6 million in Q4 2025 to a low of $18.0 million in Q3 2024.
  • A 5-year average of $26.4 million and a median of $23.1 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: tumbled 41.76% in 2024, then surged 206.43% in 2025.
  • Cartesian Therapeutics' Operating Expenses stood at $25.9 million in 2021, then fell by 2.2% to $25.3 million in 2022, then surged by 76.34% to $44.6 million in 2023, then crashed by 41.76% to $26.0 million in 2024, then soared by 206.43% to $79.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Operating Expenses are $79.6 million (Q4 2025), $21.5 million (Q3 2025), and $22.1 million (Q2 2025).